Skip to main content
Top
Published in: Archives of Virology 7/2017

01-07-2017 | Original Article

Molecular characterization of neuraminidase genes of influenza A(H3N2) viruses circulating in Southwest India from 2009 to 2013

Authors: Anitha Jagadesh, Abdul Ajees Abdul Salam, Vahid Rajabali Zadeh, Anjana Krishnan, Govindakarnavar Arunkumar

Published in: Archives of Virology | Issue 7/2017

Login to get access

Abstract

Molecular characterization of neuraminidase (NA) gene of 25 influenza A(H3N2) virus isolates (2009-2013) archived at the Manipal Centre for Virus Research was carried out. The annual rate of amino acid substitutions in the N2 gene of influenza A(H3N2) virus isolates was 0.2-0.6%. Out of the 25 NA sequences analyzed, catalytic site mutations were observed in three isolates. Two of the mutations (D151G and E276G) were detected in functional catalytic residues, and an E227V mutation was detected in the framework residues. To the best of our knowledge, NA inhibitor resistance associated with the mutations E276G and E227V has not been reported. However, the mutation D151G, which is commonly associated with culturing of influenza A(H3N2) virus in Madin-Darby canine kidney (MDCK) cells, has been reported to result in a reduction in virus susceptibility to NA inhibitor drugs. Our study also detected mutations in antigenic residues. Some of the mutations (except D197G, K249E, A250T, S334C, and H347R/N) remained conserved in isolates of succeeding seasons. Antigenic residue mutations (D197G and S334C) have not been reported globally to date. The effect of these catalytic and antigenic mutant residues on drug and antibody binding was analyzed using three-dimensional structural analysis and biochemical assays. Antigenic variability of influenza A(H3N2) viruses is a major concern, and vaccine failures are mainly due to genetic variations in the HA gene. Our study documents that genetic changes in N2 occur at a slower rate, and this information is useful for the consideration and standardization of NA in influenza vaccines.
Literature
2.
go back to reference Knipe DM, Howley PM (2013) Fields virology, 6th edn. Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia Knipe DM, Howley PM (2013) Fields virology, 6th edn. Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia
6.
go back to reference Jagadesh A, Salam AAA, Zadeh VR, Arunkumar G (2016) Genetic analysis of neuraminidase gene of influenza A(H1N1)pdm09 virus circulating in Southwest India from 2009 to 2012. J Med Virol. doi:10.1002/jmv.24625 PubMed Jagadesh A, Salam AAA, Zadeh VR, Arunkumar G (2016) Genetic analysis of neuraminidase gene of influenza A(H1N1)pdm09 virus circulating in Southwest India from 2009 to 2012. J Med Virol. doi:10.​1002/​jmv.​24625 PubMed
12.
go back to reference Lee HK, Tang JW-T, Kong DH-L et al (2013) Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage. PLoS One 8:e79252CrossRefPubMedPubMedCentral Lee HK, Tang JW-T, Kong DH-L et al (2013) Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage. PLoS One 8:e79252CrossRefPubMedPubMedCentral
13.
go back to reference Varghese JN, McKimm-Breschkin JL, Caldwell JB et al (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins Struct Funct Bioinforma 14:327–332CrossRef Varghese JN, McKimm-Breschkin JL, Caldwell JB et al (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins Struct Funct Bioinforma 14:327–332CrossRef
15.
17.
18.
go back to reference Eichelberger MC, Wan H (2014) Influenza neuraminidase as a vaccine antigen. In: Oldstone MBA, Compans RW (eds) Influenza Pathog. Control, vol. II. Springer International Publishing, Cham, pp 275–299 Eichelberger MC, Wan H (2014) Influenza neuraminidase as a vaccine antigen. In: Oldstone MBA, Compans RW (eds) Influenza Pathog. Control, vol. II. Springer International Publishing, Cham, pp 275–299
23.
24.
go back to reference Zaraket H, Kondo H, Hibino A et al (2016) Full genome characterization of human influenza A/H3N2 isolates from Asian Countries reveals a rare amantadine resistance-conferring mutation and novel PB1-F2 polymorphisms. Front Microbiol. doi:10.3389/fmicb.2016.00262 Zaraket H, Kondo H, Hibino A et al (2016) Full genome characterization of human influenza A/H3N2 isolates from Asian Countries reveals a rare amantadine resistance-conferring mutation and novel PB1-F2 polymorphisms. Front Microbiol. doi:10.​3389/​fmicb.​2016.​00262
30.
go back to reference Shil P, Chavan SS, Cherian SS (2011) Antigenic variability in Neuraminidase protein of Influenza A/H3N2 vaccine strains (1968–2009). Bioinformation 7:76–81CrossRefPubMedPubMedCentral Shil P, Chavan SS, Cherian SS (2011) Antigenic variability in Neuraminidase protein of Influenza A/H3N2 vaccine strains (1968–2009). Bioinformation 7:76–81CrossRefPubMedPubMedCentral
Metadata
Title
Molecular characterization of neuraminidase genes of influenza A(H3N2) viruses circulating in Southwest India from 2009 to 2013
Authors
Anitha Jagadesh
Abdul Ajees Abdul Salam
Vahid Rajabali Zadeh
Anjana Krishnan
Govindakarnavar Arunkumar
Publication date
01-07-2017
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 7/2017
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3306-4

Other articles of this Issue 7/2017

Archives of Virology 7/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine